Key Takeaways
- • EQT Private Equity is pursuing a $12.1 billion takeover of Qiagen NV, a life sciences testing company, according to a Wednesday announcement reported by Law360.
- • Seven law firms are advising on the take-private transaction, including Davis Polk & Wardwell LLP, Linklaters LLP and Milbank LLP.
- • The deal would take Qiagen private under Sweden-based EQT Private Equity, a notable private equity buyout of a publicly listed diagnostics company.
Summary
Sweden-based EQT Private Equity's $12.1 billion takeover of life sciences testing company Qiagen NV is drawing a large advisory group, according to Law360, which reported on October 21, 2026. The article notes that seven firms are involved on the deal, naming Davis Polk & Wardwell LLP, Linklaters LLP and Milbank LLP among them. The reporting attributes the advisory lineup to a Wednesday announcement.
The transaction is structured as a take-private, meaning Qiagen would move from public markets into private ownership under EQT. Qiagen is a life sciences company focused on sample and assay technologies and molecular diagnostics testing. The size of the deal, at $12.1 billion, places it among the larger private equity take-privates in the healthcare and diagnostics sector.
The publicly available excerpt does not include detail on offer price per share, financing structure, regulatory approvals required, or expected closing timeline. Readers seeking those terms should refer to the original announcement or subsequent filings.
The transaction is structured as a take-private, meaning Qiagen would move from public markets into private ownership under EQT. Qiagen is a life sciences company focused on sample and assay technologies and molecular diagnostics testing. The size of the deal, at $12.1 billion, places it among the larger private equity take-privates in the healthcare and diagnostics sector.
The publicly available excerpt does not include detail on offer price per share, financing structure, regulatory approvals required, or expected closing timeline. Readers seeking those terms should refer to the original announcement or subsequent filings.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.